Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open-label study of DCC-3014 in advanced tumors and tenosynovial giant cell tumor
NL-OMON54590Phase 2Recruiting
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vimseltinib in tenosynovial giant cell tumor (TGCT) and Nonhematologic neoplasms (4 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and serious adverse events and 5 more. Started Jun 2020; status: recruiting.
02
Drugs
vimseltinib
03
Conditions
tenosynovial giant cell tumor (TGCT)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON54590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54590.